Literature DB >> 27833890

Neuroanatomical changes in Parkinson's disease in relation to cognition: An update.

K G Prakash1, B M Bannur2, Madhavrao D Chavan3, K Saniya1, Kumar Sai Sailesh4, Archana Rajagopalan5.   

Abstract

The pathophysiological changes underlying impairment of cognition in Parkinson's disease (PD) are complex and not fully understood till date. Hence, understanding the structural changes responsible for cognitive decline in PD is essential for early diagnosis and to offer effective treatment. In this review, we discuss the neuroanatomical changes in major brain structures responsible for cognition in PD. We have included the key findings of various studies to provide up-to-date information for better understanding of pathophysiology of PD, which will help researchers and clinicians in planning and developing new treatment methods for the benefit of PD patients.

Entities:  

Keywords:  Cognition; Parkinson's disease; neuroanatomical changes; nonmotor features

Year:  2016        PMID: 27833890      PMCID: PMC5052937          DOI: 10.4103/2231-4040.191416

Source DB:  PubMed          Journal:  J Adv Pharm Technol Res        ISSN: 0976-2094


INTRODUCTION

Parkinson's disease (PD) is characterized by slowness of movement, rigidity, tremor, postural instability, and often cognitive impairments.[1] Although motor features are more prominent in PD, nonmotor features also have been diagnosed in PD patients.[2] Acetylcholine, norepinephrine, and serotonin may have a role in nonmotor features of PD. Features include cognitive impairment, psychological, autonomic, and sleep disorders which decrease the quality of life further.[34] The pathophysiological changes underlying impairment of cognition in PD are complex and not fully understood till date.[5] Hence, understanding the structural changes responsible for cognitive decline in PD is essential for early diagnosis and to offer effective treatment.[678] In this review, we discuss the neuroanatomical changes in major brain structures responsible for cognition in PD.

CHANGES IN BASAL GANGLIA IN PARKINSON'S DISEASE

Since changes in the morphology of basal ganglia are noticed in bipolar and unipolar disorders also, it is essential to understand the changes in basal ganglia in PD for reliable diagnosis. Basal ganglia process the signals from the cortex for accurate execution of voluntary movements.[9] Basal ganglia play a key role in cognitive functions,[10] and lesion of basal ganglia causes impairment in cognitive functions.[11] In fact, basal ganglia are the most affected brain area in PD.[12] It was reported that there were two subtypes of PD and each type will affect basal ganglia in a different fashion. The subtypes include heterogeneous clinical phenotypes such as tremor dominant (TD) and postural instability/gait difficulty (PIGD).[13] PD patients had reduced fractional anisotropy within the substantia nigra and increased mean and radial diffusivity within the substantia nigra and globus pallidus. However, microstructural changes within the substantia nigra are severely affected in PIGD patients compared to TD.[14] Reduction of the neuromelanin pigmentation, neuronal loss, and Lewy bodies are observed in the substantia nigra.[15] In PD patients, basal ganglia undergo atrophy, which depends on severity and duration of the disease.[16] In PD patients, loss of attenuation and length of the dendritic spines of medium-sized spiny neurons located in the striatum has been reported.[17] Reduction in the volumes of the caudate nucleus and thalamus and white matter is observed in PD, which may be an early sign of disease progression.[18]

CHANGES IN CEREBELLUM IN PARKINSON'S DISEASE

Increased activity of the cerebellum was observed during cognitive tasks.[19] The cerebellum has reciprocal connections with basal ganglia, and Parkinson's-related morphological changes were observed in animal models and humans.[20] These changes include significant contraction in the left cerebellum, decrease in the gray matter volume in the right quadrangular lobe.[21] These changes may be induced by degeneration of dopaminergic neurons[22] as the cerebellum receives dopaminergic projections from basal ganglia, and dopaminergic receptors were present in the cerebellum.[23]

CHANGES IN BRAIN VOLUME IN PARKINSON'S DISEASE

Strong correlation exists between brain size and cognitive functions.[24] In PD patients, atrophy of the brain was observed in many cortical and subcortical areas, which contributes in decrease in the volume of the brain.[25] Interestingly, it was reported that volume of the frontal lobe, temporoparietal junction, parietal lobe, insula, anterior cingulate cortex, basal ganglia, and thalamus increased in PD patients.[26] Prefrontal lobe plays a crucial role in cognitive functions and in PD patients; loss of gray matter has been reported.[2728]

CHANGES IN THALAMUS IN PARKINSON'S DISEASE

Thalamic lesions are found to impair cognitive functions such as language, memory, and attention.[29] Thalamic stimulation was effective in enhancement of cognition through activation of neocortex and hippocampus and modulating gene expression.[30] Approximately 30%-40% loss was reported in the thalamus in PD.[31] It was reported that volume of the thalamus decreases in PD.[18] In contrast, it was reported that thalamic shape but not volume changes in PD. As specific nuclei of the thalamus are involved in PD, atrophy of the caudal intralaminar nucleus and hypertrophy of rest of the nucleus result in altered shape of the thalamus.[32] Further, changes in white matter of the mediodorsal thalamus lead to depression in most of the PD patients.[33] Significant reduction in fractional anisotropy was reported in anterior nucleus, dorsomedial nucleus, and ventral anterior nucleus of the thalamus.[34]

CHANGES IN HYPOTHALAMUS IN PARKINSON'S DISEASE

Role of the hypothalamus in cognitive functions is well reported.[35] Impairment of hypothalamic function was reported in PD patients. Neural degeneration was observed in all 13 nuclei of the hypothalamus with predominant degeneration in tuberomamillary nucleus and the lateral and posterior hypothalamic nuclei.[36] Further, decrease in the levels of dopamine, serotonin, melanin, and hypocretin in the hypothalamus of PD patients.[37] Development of sleep, endocrine, and autonomic disorders in PD may be due to dopamine malfunction in the hypothalamus.[37] Sleep disorders may be due to loss of gray matter in hypothalamus as melatonin levels are associated with volume of gray matter.[38] As hypothalamus functioning is affected in PD, the secondary degeneration may occur to the structures directly innervated by the hypothalamus such as striatum where the dopamine synthesis occurs.[39] This further worsens the PD.

CHANGES IN LIMBIC SYSTEM IN PARKINSON'S DISEASE

Influence of limbic structures on cognition was well documented.[40] Atrophy of gray matter was observed in Parkinson's patients with dementia.[41] Dopamine dysfunction in the limbic system leads to change in the creativity and emotional dysfunction in PD patients.[42] In amygdala, accessory cortical and central nuclei are affected more by PD, and cortical, accessory basal, and granular nuclei are least affected areas.[43] Posterior cingulum is the important structure in the papez circuit which is involved in processing of episodic memory.[44] It was reported that neuronal loss, gliosis, or demyelination in the white matter and metabolic changes occurs in the cingulum of PD patients.[4445] Change in the spontaneous resting-state neural activity is reported in prefrontal cortex, which was considered as a factor for cognitive decline in PD.[46] Further, regional atrophy in the hippocampus contributes to impaired verbal learning memory and visuospatial processing.[47]

CHANGES IN LOCUS COERULEUS IN PARKINSON'S DISEASE

Loss of noradrenergic neuronal and Lewy bodies formation was much higher in locus coeruleus (LC) than dopaminergic neuronal loss in PD patients. Resting tremors of PD are due to neuronal loss of LC.[4849] About 35% of PD patients were depressed, and loss of noradrenergic pathways underlies the pathophysiology of depression in PD.[50] The pathological changes in LC of PD patients are peculiar and can be differentiated from changes that occur in other neurodegenerative diseases such as schizophrenia.[50] It was reported that simultaneous lesions of dopaminergic system, and LC causes metabolic dysfunction in the cerebral cortex and impairs cognitive functions in PD.[51]

CHANGES IN GLIAL CELLS IN PARKINSON'S DISEASE

All glial cells can influence the cognitive functions.[52] Structural changes occur in astrocytes in response to physiological and pathological conditions may influence the neurons through nonsynaptic communication with neurons.[535455] Altered neuroglial interaction may be the underlying cause for many neurological diseases including PD.[56] Glial response in PD offers both beneficial and hazardous effects.[57]

CONCLUSION

In this review, we have presented the neuroanatomical changes of major brain structures related to cognition in PD. We have included the key findings of various studies to provide up-to-date information for better understanding of pathophysiology of PD, which helps researchers and clinicians in planning and developing new treatment methods for the benefit of PD patients.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.
  49 in total

Review 1.  Mild cognitive impairment in Parkinson's disease.

Authors:  J G Goldman; I Litvan
Journal:  Minerva Med       Date:  2011-12       Impact factor: 4.806

2.  Cognitive enhancement with central thalamic electrical stimulation.

Authors:  Prasad Shirvalkar; Malika Seth; Nicholas D Schiff; Daniel G Herrera
Journal:  Proc Natl Acad Sci U S A       Date:  2006-10-25       Impact factor: 11.205

3.  Metabolic activity of cerebellar and basal ganglia-thalamic neurons is reduced in parkinsonism.

Authors:  Anne-Sophie Rolland; Maria-Trinidad Herrero; Virginia Garcia-Martinez; Merle Ruberg; Etienne C Hirsch; Chantal François
Journal:  Brain       Date:  2007-01       Impact factor: 13.501

4.  Evidence of a breakdown of corticostriatal connections in Parkinson's disease.

Authors:  B Stephens; A J Mueller; A F Shering; S H Hood; P Taggart; G W Arbuthnott; J E Bell; L Kilford; A E Kingsbury; S E Daniel; C A Ingham
Journal:  Neuroscience       Date:  2005       Impact factor: 3.590

5.  Increased prefrontal volume in PD with levodopa-induced dyskinesias: a voxel-based morphometry study.

Authors:  Antonio Cerasa; Demetrio Messina; Pierfrancesco Pugliese; Maurizio Morelli; Pierluigi Lanza; Maria Salsone; Fabiana Novellino; Giuseppe Nicoletti; Gennarina Arabia; Aldo Quattrone
Journal:  Mov Disord       Date:  2011-03-07       Impact factor: 10.338

Review 6.  Thalamic changes in Parkinson's disease.

Authors:  Glenda M Halliday
Journal:  Parkinsonism Relat Disord       Date:  2009-12       Impact factor: 4.891

7.  The hypothalamus in Parkinson disease.

Authors:  J W Langston; L S Forno
Journal:  Ann Neurol       Date:  1978-02       Impact factor: 10.422

8.  Posterior cingulate metabolic changes occur in Parkinson's disease patients without dementia.

Authors:  R M Camicioli; J R Korzan; S L Foster; N J Fisher; D J Emery; A C Bastos; C C Hanstock
Journal:  Neurosci Lett       Date:  2004-01-16       Impact factor: 3.046

9.  Cognitive impairment and dementia in Parkinson's disease: clinical features, diagnosis, and management.

Authors:  Joana Meireles; João Massano
Journal:  Front Neurol       Date:  2012-05-25       Impact factor: 4.003

10.  Shape (but not volume) changes in the thalami in Parkinson disease.

Authors:  Martin J McKeown; Ashish Uthama; Rafeef Abugharbieh; Samantha Palmer; Mechelle Lewis; Xuemei Huang
Journal:  BMC Neurol       Date:  2008-04-16       Impact factor: 2.474

View more
  12 in total

1.  Diffusion Kurtosis Imaging Detects Microstructural Changes in a Methamphetamine-Induced Mouse Model of Parkinson's Disease.

Authors:  Anas Arab; Jana Ruda-Kucerova; Alzbeta Minsterova; Eva Drazanova; Nikoletta Szabó; Zenon Starcuk; Irena Rektorova; Amit Khairnar
Journal:  Neurotox Res       Date:  2019-06-18       Impact factor: 3.911

Review 2.  Dementia with Lewy bodies and Parkinson's disease-dementia: current concepts and controversies.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2017-12-08       Impact factor: 3.575

Review 3.  Proteomics in Human Parkinson's Disease: Present Scenario and Future Directions.

Authors:  Anubhuti Dixit; Rachna Mehta; Abhishek Kumar Singh
Journal:  Cell Mol Neurobiol       Date:  2019-06-12       Impact factor: 5.046

Review 4.  Biomarkers for Parkinson's Disease: Recent Advancement.

Authors:  Sharvari Lotankar; Kedar S Prabhavalkar; Lokesh K Bhatt
Journal:  Neurosci Bull       Date:  2017-09-21       Impact factor: 5.203

5.  Early Sociability and Social Memory Impairment in the A53T Mouse Model of Parkinson's Disease Are Ameliorated by Chemogenetic Modulation of Orexin Neuron Activity.

Authors:  Milos Stanojlovic; Jean Pierre Pallais Yllescas; Aarthi Vijayakumar; Catherine Kotz
Journal:  Mol Neurobiol       Date:  2019-06-27       Impact factor: 5.590

6.  Dysregulation of mitochondrial and proteolysosomal genes in Parkinson's disease myeloid cells.

Authors:  Elisa Navarro; Evan Udine; Katia de Paiva Lopes; Madison Parks; Giulietta Riboldi; Brian M Schilder; Jack Humphrey; Gijsje J L Snijders; Ricardo A Vialle; Maojuan Zhuang; Tamjeed Sikder; Charalambos Argyrou; Amanda Allan; Michael J Chao; Kurt Farrell; Brooklyn Henderson; Sarah Simon; Deborah Raymond; Sonya Elango; Roberto A Ortega; Vicki Shanker; Matthew Swan; Carolyn W Zhu; Ritesh Ramdhani; Ruth H Walker; Winona Tse; Mary Sano; Ana C Pereira; Tim Ahfeldt; Alison M Goate; Susan Bressman; John F Crary; Lotje de Witte; Steven Frucht; Rachel Saunders-Pullman; Towfique Raj
Journal:  Nat Aging       Date:  2021-09-14

Review 7.  Endosomal Trafficking in Alzheimer's Disease, Parkinson's Disease, and Neuronal Ceroid Lipofuscinosis.

Authors:  Yasir H Qureshi; Penelope Baez; Christiane Reitz
Journal:  Mol Cell Biol       Date:  2020-09-14       Impact factor: 4.272

8.  Are dementia with Lewy bodies and Parkinson's disease dementia the same disease?

Authors:  Kurt A Jellinger; Amos D Korczyn
Journal:  BMC Med       Date:  2018-03-06       Impact factor: 8.775

9.  Neural predictors of gait stability when walking freely in the real-world.

Authors:  Sara Pizzamiglio; Hassan Abdalla; Usman Naeem; Duncan L Turner
Journal:  J Neuroeng Rehabil       Date:  2018-02-27       Impact factor: 4.262

10.  Neuroprotective and neurotoxic outcomes of androgens and estrogens in an oxidative stress environment.

Authors:  Phong Duong; Mavis A A Tenkorang; Jenny Trieu; Clayton McCuiston; Nataliya Rybalchenko; Rebecca L Cunningham
Journal:  Biol Sex Differ       Date:  2020-03-29       Impact factor: 5.027

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.